aterosklerozАтеросклерозAteroscleroz2078-256X2949-3633НИИТПМ-филиал ИЦиГ СО РАН10.52727/2078-256X-2024-20-2-183-194ateroskleroz-1057Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSХолестерин, не связанный с липопротеинами высокой плотности, и кардиометаболические заболеванияNon-high-density lipoproteins cholesterol and cardiometabolic diseaseshttps://orcid.org/0000-0002-1968-9712КаширинаА. П.KashirinaA. P.

Анастасия Петровна Каширина, младший научный сотрудник

лаборатория генетических и средовых детерминант жизненного цикла человека

630089; ул. Бориса Богаткова, 175/1; Новосибирск

Anastasia P. Kashirina, junior researcher

laboratory of genetic and environmental determinants of the human life cycle

630089; 175/1, Boris Bogatkov str.; Novosibirsk

kashrina_a_p_91@mail.ruhttps://orcid.org/0000-0002-4030-6130СимоноваГ. И.SimonovaG. I.

Галина Ильинична Симонова, д-р мед. наук, проф., главный научный сотрудник

лаборатория этиопатогенеза и клиники внутренних заболеваний

630089; ул. Бориса Богаткова, 175/1; Новосибирск

Galina I. Simonova, doctor of medical sciences, professor, chief researcher

laboratory of etiopathogenesis and clinics of internal diseases

630089; 175/1, Boris Bogatkov str.; Novosibirsk

g.simonova2019@gmail.comНаучно-исследовательский институт терапии и профилактической медицины – филиал Федерального государственного бюджетного научного учреждения «Федеральный исследовательский центр Институт цитологии и генетики Сибирского отделения Российской академии наук»Research Institute of Internal and Preventive Medicine – Branch of the Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences202405072024202183194Copyright © Каширина А.П., Симонова Г.И., 20242024Каширина А.П., Симонова Г.И.Kashirina A.P., Simonova G.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://ateroskleroz.elpub.ru/jour/article/view/1057

   На современном этапе холестерин, не связанный с липопротеинами высокой плотности (ХС неЛПВП), интенсивно изучается в качестве предиктора смертности от сердечно-сосудистых заболеваний. Повышение его содержания ассоциировано с инсулинорезистентностью, которая является патогенетическим фактором развития атерогенной (смешанной) дислипидемии, что характерно для лиц с метаболическим синдром (МС) и сахарным диабетом 2 типа (СД2). В настоящем обзоре проанализированы тенденции уровня ХС неЛПВП, начиная с 1985 г., в зарубежных странах и в Российской Федерации. Основываясь на результатах международных эпидемиологических исследований, сделаны выводы о возможности прогнозирования риска развития МС и СД2, используя в качестве маркера концентрацию ХС неЛПВП. Показана необходимость проведения проспективных когортных исследований в российской популяции, направленных на оценку роли ХС неЛПВП в ранней диагностике МС и СД2. Выполнен поиск литературных источников в электронных информационных базах данных eLIBRARY.RU и PubMed. В анализ включались исследования, результаты которых опубликованы с 1990 по 2023 гг.

   At the present stage, non-high-density lipoprotein cholesterol (non-HDL-C) is intensively studied as a predictor of mortality from cardiovascular diseases. An increase in non-HDL-C content is associated with insulin resistance, which is a pathogenetic factor in the development of atherogenic (mixed) dyslipidemia, which is typical for people with metabolic syndrome (MS) and type 2 diabetes mellitus (TDM2). This review analyzes trends in non-HDL-C level since 1985 in foreign countries and in the Russian Federation. Based on the results of international epidemiological studies, conclusions are substantiated about the possibility of predicting the risk of developing MS and type 2 diabetes using the non-HDL-C. The necessity of conducting prospective cohort studies in the Russian population aimed at assessing the role of non-HDL-C in the early diagnosis of MS and TDM2 is shown. The search for literary sources in the electronic information databases eLIBRARY.RU and PubMed. The analysis included studies published from 1990 to 2023.

холестеринне связанный с липопротеинами высокой плотностисахарный диабет 2 типаметаболический синдроматерогенная дислипидемияnon-high-density lipoprotein cholesteroltype 2 diabetes mellitusmetabolic syndromeatherogenic dyslipidemiaРабота выполнена в рамках бюджетной темы «Формирование когорт детского, подросткового, молодого населения для изучения механизмов и особенностей жизненного цикла человека в российской популяции». Рег. № 122031700115-7The work was carried out within the framework of the budget theme “Formation of cohorts of children, adolescents, young people to study the mechanisms and features of the human life cycle in the Russian population”. Reg. No. 122031700115-7ReferencesNg M., Fleming T., Robinson M, Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S., Abbafati C., Abera S.F., Abraham J.P., Abu-Rmeileh N.M., Achoki T., AlBuhairan F.S., Alemu Z.A., Alfonso R., Ali M.K., Ali R., Guzman N.A., Ammar W., Anwari P., Banerjee A., Barquera S., Basu S., Bennett D.A., Bhutta Z., Blore J., Cabral N., Nonato I.C., Chang J.C., Chowdhury R., Courville K.J., Criqui M.H., Cundiff D.K., Dabhadkar K.C., Dandona L., Davis A., Dayama A., Dharmaratne S.D., Ding E.L., Durrani A.M., Esteghamati A., Farzadfar F., Fay D.F., Feigin V.L., Flaxman A., Forouzanfar M.H., Goto A., Green M.A., Gupta R., Hafezi-Nejad N., Hankey G.J., Harewood H.C., Havmoeller R., Hay S., Hernandez L., Husseini A., Idrisov B.T., Ikeda N., Islami F., Jahangir E., Jassal S.K., Jee S.H., Jeffreys M., Jonas J.B., Kabagambe E.K., Khalifa S.E., Kengne A.P., Khader Y.S., Khang Y.H., Kim D., Kimokoti R.W., Kinge J.M., Kokubo Y., Kosen S., Kwan G., Lai T., Leinsalu M., Li Y., Liang X., Liu S., Logroscino G., Lotufo P.A., Lu Y., Ma J., Mainoo N.K., Mensah G.A., Merriman T.R., Mokdad A.H., Moschandreas J., Naghavi M., Naheed A., Nand D., Narayan K.M., Nelson E.L., Neuhouser M.L., Nisar M.I., Ohkubo T., Oti S.O., Pedroza A., Prabhakaran D., Roy N., Sampson U., Seo H., Sepanlou S.G., Shibuya K., Shiri R., Shiue I., Singh G.M., Singh J.A., Skirbekk V., Stapelberg N.J., Sturua L., Sykes B.L., Tobias M., Tran B.X., Trasande L., Toyoshima H., van de Vijver S., Vasankari T.J., Veerman J.L., Velasquez-Melendez G., Vlassov V.V., Vollset S.E., Vos T., Wang C., Wang X., Weiderpass E., Werdecker A., Wright J.L., Yang Y.C., Yatsuya H., Yoon J., Yoon S.J., Zhao Y., Zhou M., Zhu S., Lopez A.D., Murray C.J., Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014; 384 (9945): 766–781. doi: 10.1016/S0140-6736(14)60460-8Ng M., Fleming T., Robinson M, Thomson B., Graetz N., Margono C., Mullany E.C., Biryukov S., Abbafati C., Abera S.F., Abraham J.P., Abu-Rmeileh N.M., Achoki T., AlBuhairan F.S., Alemu Z.A., Alfonso R., Ali M.K., Ali R., Guzman N.A., Ammar W., Anwari P., Banerjee A., Barquera S., Basu S., Bennett D.A., Bhutta Z., Blore J., Cabral N., Nonato I.C., Chang J.C., Chowdhury R., Courville K.J., Criqui M.H., Cundiff D.K., Dabhadkar K.C., Dandona L., Davis A., Dayama A., Dharmaratne S.D., Ding E.L., Durrani A.M., Esteghamati A., Farzadfar F., Fay D.F., Feigin V.L., Flaxman A., Forouzanfar M.H., Goto A., Green M.A., Gupta R., Hafezi-Nejad N., Hankey G.J., Harewood H.C., Havmoeller R., Hay S., Hernandez L., Husseini A., Idrisov B.T., Ikeda N., Islami F., Jahangir E., Jassal S.K., Jee S.H., Jeffreys M., Jonas J.B., Kabagambe E.K., Khalifa S.E., Kengne A.P., Khader Y.S., Khang Y.H., Kim D., Kimokoti R.W., Kinge J.M., Kokubo Y., Kosen S., Kwan G., Lai T., Leinsalu M., Li Y., Liang X., Liu S., Logroscino G., Lotufo P.A., Lu Y., Ma J., Mainoo N.K., Mensah G.A., Merriman T.R., Mokdad A.H., Moschandreas J., Naghavi M., Naheed A., Nand D., Narayan K.M., Nelson E.L., Neuhouser M.L., Nisar M.I., Ohkubo T., Oti S.O., Pedroza A., Prabhakaran D., Roy N., Sampson U., Seo H., Sepanlou S.G., Shibuya K., Shiri R., Shiue I., Singh G.M., Singh J.A., Skirbekk V., Stapelberg N.J., Sturua L., Sykes B.L., Tobias M., Tran B.X., Trasande L., Toyoshima H., van de Vijver S., Vasankari T.J., Veerman J.L., Velasquez-Melendez G., Vlassov V.V., Vollset S.E., Vos T., Wang C., Wang X., Weiderpass E., Werdecker A., Wright J.L., Yang Y.C., Yatsuya H., Yoon J., Yoon S.J., Zhao Y., Zhou M., Zhu S., Lopez A.D., Murray C.J., Gakidou E. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2014; 384 (9945): 766–781. doi: 10.1016/S0140-6736(14)60460-8Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А., Сазонова Д.В., Мокрышева Н.Г. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010–2022 гг. Сахарный диабет, 2023; 26(2): 104–123. doi: 10.14341/DM13035.Dedov I.I., Shestakova M.V., Vikulova O.K., Zheleznyakova A.V., Isakov M.A., Sazonova D.V., Mokrysheva N.G. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus, 2023; 26 (2): 104–123. (In Russ.). doi: 10.14341/DM13035Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep., 2012; 14 (1): 1–10. doi: 10.1007/s11883-011-0219-7Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr. Atheroscler. Rep., 2012; 14 (1): 1–10. doi: 10.1007/s11883-011-0219-7Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metab. Cardiovasc. Dis., 2013; 23 (9): 799–807. doi: 10.1016/j.numecd.2013.05.002Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Nutr. Metab. Cardiovasc. Dis., 2013; 23 (9): 799–807. doi: 10.1016/j.numecd.2013.05.002Behbodikhah J., Ahmed S., Elyasi A., Kasselman L.J., de Leon J., Glass A.D., Reiss A.B. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites, 2021; 11 (10): 690. doi: 10.3390/metabo11100690Behbodikhah J., Ahmed S., Elyasi A., Kasselman L.J., de Leon J., Glass A.D., Reiss A.B. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites, 2021; 11 (10): 690. doi: 10.3390/metabo11100690Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., Furberg C.D. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes, 2011; 4 (3): 337–345. doi: 10.1161/CIRCOUTCOMES.110.959247Sniderman A.D., Williams K., Contois J.H., Monroe H.M., McQueen M.J., de Graaf J., Furberg C.D. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ. Cardiovasc. Qual. Outcomes, 2011; 4 (3): 337–345. doi: 10.1161/CIRCOUTCOMES.110.959247Ulloque-Badaracco J.R., Al-Kassab-Córdova A., Hernandez-Bustamante E.A., Alarcon-Braga E.A., Huayta-Cortez M., Carballo-Tello X.L., Seminario-Amez R.A., Herrera-Añazco P., Benites-Zapata V.A. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome : a systematic review and meta-analysis. Lipids. Health Dis., 2023; 22 (1): 98. doi: 10.1186/s12944-023-01860-wUlloque-Badaracco J.R., Al-Kassab-Córdova A., Hernandez-Bustamante E.A., Alarcon-Braga E.A., Huayta-Cortez M., Carballo-Tello X.L., Seminario-Amez R.A., Herrera-Añazco P., Benites-Zapata V.A. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome : a systematic review and meta-analysis. Lipids. Health Dis., 2023; 22 (1): 98. doi: 10.1186/s12944-023-01860-wLanglois M.R., Nordestgaard B.G., Langsted A., Chapman M.J., Aakre K.M., Baum H., Borén J., Bruckert E., Catapano A., Cobbaert C., Collinson P., Descamps O.S., Duff C.J., von Eckardstein A., Hammerer-Lercher A., Kamstrup P.R., Kolovou G., Kronenberg F., Mora S., Pulkki K., Remaley A.T., Rifai N., Ros E., Stankovic S., Stavljenic-Rukavina A., Sypniewska G., Watts G.F., Wiklund O., Laitinen P.; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin. Chem. Lab. Med., 2020; 58 (4): 496–517. doi: 10.1515/cclm-2019-1253Langlois M.R., Nordestgaard B.G., Langsted A., Chapman M.J., Aakre K.M., Baum H., Borén J., Bruckert E., Catapano A., Cobbaert C., Collinson P., Descamps O.S., Duff C.J., von Eckardstein A., Hammerer-Lercher A., Kamstrup P.R., Kolovou G., Kronenberg F., Mora S., Pulkki K., Remaley A.T., Rifai N., Ros E., Stankovic S., Stavljenic-Rukavina A., Sypniewska G., Watts G.F., Wiklund O., Laitinen P.; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin. Chem. Lab. Med., 2020; 58 (4): 496–517. doi: 10.1515/cclm-2019-1253Brunner F.J., Waldeyer C., Ojeda F., Salomaa V., Kee F., Sans S., Thorand B., Giampaoli S., Brambilla P., Tunstall-Pedoe H., Moitry M., Iacoviello L., Veronesi G., Grassi G., Mathiesen E.B., Söderberg S., Linneberg A., Brenner H., Amouyel P., Ferrières J., Tamosiunas A., Nikitin Yu.P., Drygas W., Melander O., Jöckel K.H., Leistner D.M., Shaw J.E., Panagiotakos D.B., Simons L.A., Kavousi M., Vasan R.S., Dullaart R.P., Wannamethee S.G., Risérus U., Shea S., de Lemos J.A., Omland T., Kuulasmaa K., Landmesser U., Blankenberg S.; Multinational Cardiovascular Risk Consortium. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet, 2019; 394 (10215): 2173–2183. doi: 10.1016/S0140-6736(19)32519-XBrunner F.J., Waldeyer C., Ojeda F., Salomaa V., Kee F., Sans S., Thorand B., Giampaoli S., Brambilla P., Tunstall-Pedoe H., Moitry M., Iacoviello L., Veronesi G., Grassi G., Mathiesen E.B., Söderberg S., Linneberg A., Brenner H., Amouyel P., Ferrières J., Tamosiunas A., Nikitin Yu.P., Drygas W., Melander O., Jöckel K.H., Leistner D.M., Shaw J.E., Panagiotakos D.B., Simons L.A., Kavousi M., Vasan R.S., Dullaart R.P., Wannamethee S.G., Risérus U., Shea S., de Lemos J.A., Omland T., Kuulasmaa K., Landmesser U., Blankenberg S.; Multinational Cardiovascular Risk Consortium. Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium. Lancet, 2019; 394 (10215): 2173–2183. doi: 10.1016/S0140-6736(19)32519-XVisseren F.L., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H., Halvorsen S., Hobbs F.D., Hollander M., Jankowska E.A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K.P., van Dis I., van Gelder I.C., Wanner C., Williams B.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J., 2021; 42 (34): 3227–3337. doi: 10.1093/eurheartj/ehab484Visseren F.L., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., Cosyns B., Crawford C., Davos C.H., Desormais I., Di Angelantonio E., Franco O.H., Halvorsen S., Hobbs F.D., Hollander M., Jankowska E.A., Michal M., Sacco S., Sattar N., Tokgozoglu L., Tonstad S., Tsioufis K.P., van Dis I., van Gelder I.C., Wanner C., Williams B.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J., 2021; 42 (34): 3227–3337. doi: 10.1093/eurheartj/ehab484Ежов М.В., Кухарчук В В., Сергиенко И В., Алиева А.С., Анциферов М.Б., Аншелес А.А., Арабидзе Г.Г., Аронов Д.М., Арутюнов Г.П., Ахмеджанов Н.М., Балахонова Т.В., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галстян Г.Р., Галявич А.С., Горнякова Н.Б., Гуревич В.С., Дедов И.И., Драпкина О.М., Дупляков Д.В., Ерегин С.Я., Ершова А.И., Иртюга О.Б., Карпов С.Р., Карпов Ю.А., Качковский М.А., Кобалава Ж.Д., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачева Е.Д., Котовская Ю.В., Мартынов А.И., Мешков А.Н., Небиеридзе Д.В., Недогода С.В., Обрезан А.Г., Олейников В.Э., Покровский С.Н., Рагино Ю.И., Ротарь О.П., Скибицкий В.В., Смоленская О.Г., Соколов А.А., Сумароков А.Б., Филиппов А.Е., Халимов Ю.Ш., Чазова И.Е., Шапошник И.И., Шестакова М.В., Якушин С.С., Шляхто Е.В. Нарушения липидного обмена. Клинические рекомендации 2023. Рос. кардиол. журн., 2023; 28 (5): 250–297. doi:10.15829/1560-4071-2023-5471.Ezhov M.V., Kukharchuk V.V., Sergienko I.V., Alieva A.S., Antsiferov M.B., Ansheles A.A., Arabidze G.G., Aronov D.M., Arutyunov G.P., Akhmedzhanov N.M., Balakhonova T.V., Barbarash O.L., Boytsov S.A., Bubnova M.G., Voevoda M.I., Galstyan G.R., Galyavich A.S., Gornyakova N.B., Gurevich V.S., Dedov I.I., Drapkina O.M., Duplyakov D.V., Eregin S.Ya., Ershova A.I., Irtyuga O.B., Karpov R.S., Karpov Yu.A., Kachkovsky M.A., Kobalava Zh.D., Koziolova N.A., Konovalov G.A., Konstantinov V.O., Kosmacheva E.D., Kotovskaya Yu.V., Martynov A.I., Meshkov A.N., Nebieridze D.V., Nedogoda S.V., Obrezan A.G., Oleinikov V.E., Pokrovsky S.N., Ragino Yu.I., Rotar O.P., Skibitsky V.V., Smolenskaya O.G., Sokolov A.A., Sumarokov A.B., Filippov E., Halimov Yu.Sh., Chazova I.E., Shaposhnik I.I., Shestakova M.V., Yakushin S.S., Shlyakhto E.V. Disorders of lipid metabolism. Clinical Guidelines 2023. Russian Journal of Cardiology, 2023; 28 (5): 250–297. (In Russ.). doi: 10.15829/1560-4071-2023-5471Holme I., Aastveit A.H., Jungner I., Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med., 2008; 264 (1): 30–38. doi: 10.1111/j.1365-2796.2008.01925.xHolme I., Aastveit A.H., Jungner I., Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RISk study (AMORIS). J. Intern. Med., 2008; 264 (1): 30–38. doi: 10.1111/j.1365-2796.2008.01925.xCarroll M.D., Kit B.K., Lacher D.A., Shero S.T., Mussolino M.E. Trends in lipids and lipoproteins in US adults, 1988–2010. JAMA, 2012; 308 (15): 1545–1554. doi: 10.1001/jama.2012.13260Carroll M.D., Kit B.K., Lacher D.A., Shero S.T., Mussolino M.E. Trends in lipids and lipoproteins in US adults, 1988–2010. JAMA, 2012; 308 (15): 1545–1554. doi: 10.1001/jama.2012.13260Никитин Ю.П., Макаренкова К.В., Малютина С.К., Паяк А., Кубинова Р., Пизи А., Бобак М. Липидные параметры крови в российской, польской и чешской популяциях: The Hapiee Study. Кардиология, 2015; 55 (5): 34–39. URL: https://translated.turbopages.org/proxy_u/en-ru.ru.840f77ce-6687a71d-c4c2434b-74722d776562/https/pubmed.ncbi.nlm.nih.gov:443/26615622/.Nikitin Yu.P., Makarenkova K.V., Malyutina S.K., Pajak A., Kubinova R., Peasey A., Bobak M. Blood lipid parameters in populations of Russia, Poland and Czech Republic: The HAPIEE study. Kardiologiia, 2015; 55 (5): 34–39. (In Russ.). URL: https://translated.turbopages.org/proxy_u/en-ru.ru.840f77ce-6687a71d-c4c2434b-74722d776562/https/pubmed.ncbi.nlm.nih.gov:443/26615622/Zhou L., Zhao X., Heizhati M., Abulikemu S., Zhang D., Cheng Q., Ouyang W., Yao X., Hong J., Wu T., Xiamili Z., Li N. Trends in lipids and lipoproteins among adults in Northwestern Xinjiang, China, from 1998 through 2015. J. Epidemiol., 2019; 29 (7): 257–263. doi: 10.2188/jea.JE20180018Zhou L., Zhao X., Heizhati M., Abulikemu S., Zhang D., Cheng Q., Ouyang W., Yao X., Hong J., Wu T., Xiamili Z., Li N. Trends in lipids and lipoproteins among adults in Northwestern Xinjiang, China, from 1998 through 2015. J. Epidemiol., 2019; 29 (7): 257–263. doi: 10.2188/jea.JE20180018Kwon Y.J., Lee J.W., Kang H.T. Secular trends in lipid profiles in Korean adults based on the 2005–2015 KNHANES. Int. J. Environ. Res. Public Health, 2019; 16 (14): 2555. doi: 10.3390/ijerph16142555Kwon Y.J., Lee J.W., Kang H.T. Secular trends in lipid profiles in Korean adults based on the 2005–2015 KNHANES. Int. J. Environ. Res. Public Health, 2019; 16 (14): 2555. doi: 10.3390/ijerph16142555NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020 ;582 (7810): 73–77. doi: 10.1038/s41586-020-2338-1NCD Risk Factor Collaboration (NCD-RisC). Repositioning of the global epicentre of non-optimal cholesterol. Nature, 2020 ;582 (7810): 73–77. doi: 10.1038/s41586-020-2338-1NCD Risk Factor Collaboration (NCD-RisC). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int. J. Epidemiol.б 2020; 49 (1): 173–192. doi: 10.1093/ije/dyz099NCD Risk Factor Collaboration (NCD-RisC). National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int. J. Epidemiol.б 2020; 49 (1): 173–192. doi: 10.1093/ije/dyz099Никитин Ю.П., Макаренкова К.В., Малютина С.К. Многолетние тренды основных липидных параметров крови в сибирской популяции. Кардиоваскуляр. терапия и профилактика, 2014; 13 (3): 32–35. doi: 10.15829/1728-8800-2014-3-32-35.Nikitin Yu.P., Malyutina S.K., Makarenkova K.V. Long-term trends of the main blood lipid parameters in siberian population. Cardiovascular Therapy and Prevention,. 2014; 13 (3): 32–35. (In Russ.). doi: 10.15829/1728-8800-2014-3-32-35Симонова Г.И., Богатырев С.Н., Опенко Т.Г., Щербакова Л.В., Никитин Ю.П. 23-летние тренды смертности в городской сибирской популяции. Бюллетень Сибирского отделения Российской академии медицинских наук, 2011; 31 (1): 96–101.Simonova G.I., Bogatyrev S.N., Openko T.G., Shcherbakova L.V., Nikitin Yu.P. 23-years trends of mortality in urban Siberian population. Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences, 2011; 31 (1): 96–101. (In Russ.)Шальнова С.А., Метельская В.А., Куценко В.А., Яровая Е.Б., Капустина А.В., Муромцева Г.А., Свинин Г.Е., Баланова Ю.А., Имаева А.Э., Евстифеева С.Е., Вилков В.Г., Барбараш О.Л., Белова О.А., Гринштейн Ю.И., Ефанов А.Ю., Калачикова О.Н., Кулакова Н.В., Ротарь О.П., Трубачева И.А., Дупляков Д.В., Либис Р.А., Викторова И.А., Редько А.Н., Якушин С.С., Бойцов С.А., Шляхто Е.В., Драпкина О.М. Холестерин, не входящий в состав липопротеинов высокой плотности: современный ориентир оценки нарушений липидного обмена. Рациональная фармакотерапия в кардиологии, 2022; 18 (4): 366–375. doi: 10.20996/1819-6446-2022-07-01.Shalnova S.A., Metelskaya V.A., Kutsenko V.A., Yarovaya E.B., Kapustina A.V., Muromtseva G.A., Svinin G.E., Balanova Yu.A., Imaeva A.E., Evstifeeva S.E., Vilkov V.G., Barbarash O.L., Belova O.A., Grinshtein Yu.I., Efanov A.Yu., Kalachikova O.N., Kulakova N.V., Rotar O.P., Trubacheva I.A., Duplyakov D.V., Libis R.A., Viktorova I.A., Redko A.N., Yakushin S.S., Boytsov S.A., Shlyakhto E.V., Drapkina O.M. The non-high density lipoprotein cholesterol: a modern benchmark for assessing lipid metabolism disorders. Rational Pharmacotherapy in Cardiology, 2022; 18 (4): 366–375. (In Russ.). doi: 10.20996/1819-6446-2022-07-01Calling S., Johansson S.E., Wolff M., Sundquist J., Sundquist K. Total cholesterol/HDL-C ratio versus non-HDL-C as predictors for ischemic heart disease: a 17-year follow-up study of women in southern Sweden. BMC Cardiovasc. Disord., 2021; 21 (1): 163. doi: 10.1186/s12872-021-01971-1Calling S., Johansson S.E., Wolff M., Sundquist J., Sundquist K. Total cholesterol/HDL-C ratio versus non-HDL-C as predictors for ischemic heart disease: a 17-year follow-up study of women in southern Sweden. BMC Cardiovasc. Disord., 2021; 21 (1): 163. doi: 10.1186/s12872-021-01971-1Huang Y., Yan M.Q., Zhou D., Chen C.L., Feng Y.Q. The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. Front. Cardiovasc. Med., 2023; 10: 1065750. doi: 10.3389/fcvm.2023.1065750Huang Y., Yan M.Q., Zhou D., Chen C.L., Feng Y.Q. The U-shaped association of non-high-density lipoprotein cholesterol with all-cause and cardiovascular mortality in general adult population. Front. Cardiovasc. Med., 2023; 10: 1065750. doi: 10.3389/fcvm.2023.1065750Abdullah S.M., Defina L.F., Leonard D., Barlow C.E., Radford N.B., Willis B.L., Rohatgi A., McGuire D.K., de Lemos J.A., Grundy S.M., Berry J.D., Khera A. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation, 2018; 138 (21): 2315–2325. doi: 10.1161/CIRCULATIONAHA.118.034273Abdullah S.M., Defina L.F., Leonard D., Barlow C.E., Radford N.B., Willis B.L., Rohatgi A., McGuire D.K., de Lemos J.A., Grundy S.M., Berry J.D., Khera A. Long-term association of low-density lipoprotein cholesterol with cardiovascular mortality in individuals at low 10-year risk of atherosclerotic cardiovascular disease. Circulation, 2018; 138 (21): 2315–2325. doi: 10.1161/CIRCULATIONAHA.118.034273Cheng Q., Liu X.C., Chen C.L., Huang Y.Q., Feng Y.Q., Chen J.Y. The U-shaped association of non-high-density lipoprotein cholesterol levels with all-cause and cardiovascular mortality among patients with hypertension. Front. Cardiovasc. Med., 2021; 8: 707701. doi: 10.3389/fcvm.2021.707701Cheng Q., Liu X.C., Chen C.L., Huang Y.Q., Feng Y.Q., Chen J.Y. The U-shaped association of non-high-density lipoprotein cholesterol levels with all-cause and cardiovascular mortality among patients with hypertension. Front. Cardiovasc. Med., 2021; 8: 707701. doi: 10.3389/fcvm.2021.707701Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., de Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020; 41 (1): 111–188. doi: 10.1093/eurheartj/ehz455Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., de Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R., Riccardi G., Richter D.J., Sabatine M.S., Taskinen M.R., Tokgozoglu L., Wiklund O.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020; 41 (1): 111–188. doi: 10.1093/eurheartj/ehz455Raja V., Aguiar C., Alsayed N., Chibber Y.S., El-Badawi H., Ezhov M., Hermans M.P., Pandey R.C., Ray K.K., Tokgözoglu L., Zambon A., Berrou J.P., Farnier M. Non-HDL-cholesterol in dyslipidemia : Review of the state-of-the-art literature and outlook. Atherosclerosis, 2023; 383: 117312. doi: 10.1016/j.atherosclerosis.2023.117312Raja V., Aguiar C., Alsayed N., Chibber Y.S., El-Badawi H., Ezhov M., Hermans M.P., Pandey R.C., Ray K.K., Tokgözoglu L., Zambon A., Berrou J.P., Farnier M. Non-HDL-cholesterol in dyslipidemia : Review of the state-of-the-art literature and outlook. Atherosclerosis, 2023; 383: 117312. doi: 10.1016/j.atherosclerosis.2023.117312Haffner S.M. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care, 2004; 27 (1): 68–71. doi: 10.2337/diacare.27.2007.s68Haffner S.M. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care, 2004; 27 (1): 68–71. doi: 10.2337/diacare.27.2007.s68Butnariu L.I., Gorduza E.V., Țarcă E., Pânzaru M.C., Popa S., Stoleriu S., Lupu V.V., Lupu A., Cojocaru E., Trandafir L.M., Moisă Ș.M., Florea A., Stătescu L., Bădescu M.C. Current data and new insights into the genetic factors of atherogenic dyslipidemia associated with metabolic syndrome. Diagnostics (Basel), 2023; 13 (14): 2348. doi: 10.3390/diagnostics13142348Butnariu L.I., Gorduza E.V., Țarcă E., Pânzaru M.C., Popa S., Stoleriu S., Lupu V.V., Lupu A., Cojocaru E., Trandafir L.M., Moisă Ș.M., Florea A., Stătescu L., Bădescu M.C. Current data and new insights into the genetic factors of atherogenic dyslipidemia associated with metabolic syndrome. Diagnostics (Basel), 2023; 13 (14): 2348. doi: 10.3390/diagnostics13142348Fahed G., Aoun L., Bou Zerdan M., Allam S., Bouferraa Y., Assi H.I. Metabolic syndrome: updates on pathophysiology and management in 2021. Int. J. Mol. Sci., 2022; 23 (2): 786. doi: 10.3390/ijms23020786Fahed G., Aoun L., Bou Zerdan M., Allam S., Bouferraa Y., Assi H.I. Metabolic syndrome: updates on pathophysiology and management in 2021. Int. J. Mol. Sci., 2022; 23 (2): 786. doi: 10.3390/ijms23020786Mardi P., Abdi F., Ehsani A., Seif E., Djalalinia S., Heshmati J., Shahrestanaki E., Gorabi A.M., Qorbani M. Is non-high-density lipoprotein associated with metabolic syndrome? A systematic review and meta-analysis. Front. Endocrinol. (Lausanne), 2022; 13: 957136. doi: 10.3389/fendo.2022.957136Mardi P., Abdi F., Ehsani A., Seif E., Djalalinia S., Heshmati J., Shahrestanaki E., Gorabi A.M., Qorbani M. Is non-high-density lipoprotein associated with metabolic syndrome? A systematic review and meta-analysis. Front. Endocrinol. (Lausanne), 2022; 13: 957136. doi: 10.3389/fendo.2022.957136Tóth P.P., Potter D., Ming E.E. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006. J. Clin. Lipidol., 2012; 6 (4): 325–330. doi: 10.1016/j.jacl.2012.05.002Tóth P.P., Potter D., Ming E.E. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003–2006. J. Clin. Lipidol., 2012; 6 (4): 325–330. doi: 10.1016/j.jacl.2012.05.002Симонова Г.И., Мустафина С.В., Рымар О.Д., Малютина С.К., Щербакова Л.В., Каширина А.П., Никитин Ю.П., Рагино Ю.И. Ассоциации холестерина липопротеинов невысокой плотности с метаболическим синдромом, диабетом и артериальной гипертензией в популяции 45–69 лет. Артериальная гипертензия, 2022; 28 (5): 501–517. doi: 10.18705/1607-419X-2022-28-5-501-517.Simonova G.I., Mustafina S.V., Rymar O.D., Malyutina S.K., Shcherbakova L.V., Kashirina A.P., Nikitin Yu.P., Ragino Yu.I. Association of non-high-density lipoprotein hypercholesterol with metabolic syndrome, diabetes and arterial hypertension in the population of 45–69 years adults. Arterial Hypertension, 2022; 28 (5): 501–517. (In Russ.). doi: 10.18705/1607-419X-2022-28-5-501-517Liu A., Reaven G.M. Is measurement of non-HDL cholesterol an effective way to identify the metabolic syndrome? Nutrition, metabolism, and cardiovascular diseases: NMCD, 2013; 23 (11): 1122–1127. doi:10.1016/j.numecd.2012.12.001Liu A., Reaven G.M. Is measurement of non-HDL cholesterol an effective way to identify the metabolic syndrome? Nutrition, metabolism, and cardiovascular diseases: NMCD, 2013; 23 (11): 1122–1127. doi:10.1016/j.numecd.2012.12.001Wang S., Tu J., Pan Y. Threshold effects in the relationship between serum non-high-dnsity lipoprotein cholesterol and metabolic syndrome. Diabetes Metab. Syndr. Obes., 2019; 12: 2501–2506. doi: 10.2147/DMSO.S232343Wang S., Tu J., Pan Y. Threshold effects in the relationship between serum non-high-dnsity lipoprotein cholesterol and metabolic syndrome. Diabetes Metab. Syndr. Obes., 2019; 12: 2501–2506. doi: 10.2147/DMSO.S232343Ghodsi S., Meysamie A., Abbasi M., Ghalehtaki R., Esteghamati A., Malekzadeh M.M., Asgari F., Gouya M.M. Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. J. Diabetes Metab. Disord., 2017; 16: 25. doi: 10.1186/s40200-017-0306-6Ghodsi S., Meysamie A., Abbasi M., Ghalehtaki R., Esteghamati A., Malekzadeh M.M., Asgari F., Gouya M.M. Non-high-density lipoprotein fractions are strongly associated with the presence of metabolic syndrome independent of obesity and diabetes: a population-based study among Iranian adults. J. Diabetes Metab. Disord., 2017; 16: 25. doi: 10.1186/s40200-017-0306-6Vazirian F., Darroudi S., Rahimi H.R., Latifi M., Shakeri B., Abolbashari S., Mohammadpour A.H., Esmaily H., Mouhebati M., Samadi S., Mobarhan M.G. Non-HDL cholesterol and long-term follow-up outcomes in patients with metabolic syndrome. Lipids Health Dis., 2023; 22 (1): 165. doi: 10.1186/s12944-023-01923-yVazirian F., Darroudi S., Rahimi H.R., Latifi M., Shakeri B., Abolbashari S., Mohammadpour A.H., Esmaily H., Mouhebati M., Samadi S., Mobarhan M.G. Non-HDL cholesterol and long-term follow-up outcomes in patients with metabolic syndrome. Lipids Health Dis., 2023; 22 (1): 165. doi: 10.1186/s12944-023-01923-yАметов А.С., Курочкин И.О., Зубков А.А. Сахарный диабет и сердечно-сосудистые заболевания. РМЖ, 2014; 22 (13): 943–958.Ametov A.S., Kurochkin I.O., Zubkov A.A. Diabetes mellitus and cardiovascular diseases. RMZh, 2014; 22 (13): 943–958. (In Russ.)Peters S.A., Huxley R.R., Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men : a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia, 2014; 57 (8): 1542–1551. doi: 10.1007/s00125-014-3260-6Peters S.A., Huxley R.R., Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men : a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia, 2014; 57 (8): 1542–1551. doi: 10.1007/s00125-014-3260-6Гуревич В.С., Козиолова Н.А., Ежов М.В., Cергиенко И.В., Алиева А.С., Вавилова Т.В., Панов А.В., Обрезан А.Г., Калашников В.Ю., Арутюнов Г.П., Константинов В.О. Нерешенные проблемы дислипидемии и резидуального сердечно-сосудистого риска. Атеросклероз и дислипидемии, 2022; 1 (46): 31–38. doi: 10.34687/2219-8202.JAD.2022.01.0003].Gurevich V.S., Koziolova N.A., Ezhov M.V., Sergienko I.V., Alieva A.S., Vavilova T.V. Panov A.V., Obrezan A.G., Kalashnikov V.Yu., Arutyunov G.P., Konstantinov V.O. Unsolved problems of dyslipidemia and residual cardiovascular risk. J. Atherosclerosis Dyslipidemias, 2022; 1 (46): 31–38. (In Russ.). doi: 10.34687/2219-8202.JAD.2022.01.0003Cao Y., Yan L., Guo N., Yu N., Wang Y., Cao X., Yang S., Lv F. Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes : A systematic review and meta-analysis. Diabetes Res. Clin. Pract., 2019; 147: 1–8. doi: 10.1016/j.diabres.2018.11.002Cao Y., Yan L., Guo N., Yu N., Wang Y., Cao X., Yang S., Lv F. Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes : A systematic review and meta-analysis. Diabetes Res. Clin. Pract., 2019; 147: 1–8. doi: 10.1016/j.diabres.2018.11.002Li C., Ford E.S., Tsai J., Zhao G., Balluz L.S., Gidding S.S. Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. Cardiovasc. Diabetol., 2011; 10: 46. doi: 10.1186/1475-2840-10-46Li C., Ford E.S., Tsai J., Zhao G., Balluz L.S., Gidding S.S. Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. Cardiovasc. Diabetol., 2011; 10: 46. doi: 10.1186/1475-2840-10-46Zhou Y., Yang G., Qu C., Chen J., Qian Y., Yuan L., Mao T., Xu Y., Li X., Zhen S., Liu S. Predictive performance of lipid parameters in identifying undiagnosed diabetes and prediabetes: a cross-sectional study in eastern China. BMC Endocr. Disord., 2022; 22 (1): 76. doi: 10.1186/s12902-022-00984-xZhou Y., Yang G., Qu C., Chen J., Qian Y., Yuan L., Mao T., Xu Y., Li X., Zhen S., Liu S. Predictive performance of lipid parameters in identifying undiagnosed diabetes and prediabetes: a cross-sectional study in eastern China. BMC Endocr. Disord., 2022; 22 (1): 76. doi: 10.1186/s12902-022-00984-xGuo W., Qin P., Lu J., Li X., Zhu W., Xu N., Wang J., Zhang Q. Diagnostic values and appropriate cutoff points of lipid ratios in patients with abnormal glucose tolerance status: a cross-sectional study. Lipids Health Dis., 2019; 18 (1): 130. doi: 10.1186/s12944-019-1070-zGuo W., Qin P., Lu J., Li X., Zhu W., Xu N., Wang J., Zhang Q. Diagnostic values and appropriate cutoff points of lipid ratios in patients with abnormal glucose tolerance status: a cross-sectional study. Lipids Health Dis., 2019; 18 (1): 130. doi: 10.1186/s12944-019-1070-zHwang Y.C., Ahn H.Y., Park S.W., Park C.Y. Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. Acta Diabetol., 2014; 51 (6): 941–946. doi: 10.1007/s00592-014-0587-xHwang Y.C., Ahn H.Y., Park S.W., Park C.Y. Apolipoprotein B and non-HDL cholesterol are more powerful predictors for incident type 2 diabetes than fasting glucose or glycated hemoglobin in subjects with normal glucose tolerance: a 3.3-year retrospective longitudinal study. Acta Diabetol., 2014; 51 (6): 941–946. doi: 10.1007/s00592-014-0587-xSeo I.H., Son D.H., Lee H.S., Lee Y.J. Non-HDL cholesterol as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years. Transl. Res., 2022; 243: 52–59. doi: 10.1016/j.trsl.2021.12.008Seo I.H., Son D.H., Lee H.S., Lee Y.J. Non-HDL cholesterol as a predictor for incident type 2 diabetes in community-dwelling adults: longitudinal findings over 12 years. Transl. Res., 2022; 243: 52–59. doi: 10.1016/j.trsl.2021.12.008Sheng G., Liu D., Kuang M., Zhong Y., Zhang S., Zou Y. Utility of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in evaluating incident diabetes risk. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022; 15: 1677–1686. doi: 10.2147/DMSO.S355980Sheng G., Liu D., Kuang M., Zhong Y., Zhang S., Zou Y. Utility of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio in evaluating incident diabetes risk. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022; 15: 1677–1686. doi: 10.2147/DMSO.S355980

The authors declare that there are no conflicts of interest present.